about
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.Postprostatectomy radiation therapy for prostate cancer.Feasibility and Initial Dosimetric Findings for a Randomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imaging-Defined Targets in Prostate Cancer.Dynamic contrast-enhanced MRI for automatic detection of foci of residual or recurrent disease after prostatectomy.Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study.Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis.Head and neck second primary cancer rates in the human papillomavirus era: A population-based analysis.Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study.Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison.Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.Automatic Detection and Quantitative DCE-MRI Scoring of Prostate Cancer Aggressiveness.Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.Assessment of Rigid Registration Quality Measures in Ultrasound-Guided Radiotherapy.Quantification of the margin required for treating intraprostatic lesions.Prostate cancer: Moderate hypofractionated radiotherapy - not yet a standard of care.Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapyContemporary role of postoperative radiotherapy for prostate cancerAssessment of specific versus combined purpose knowledge based models in prostate radiotherapyAutomatic Detection of Prostate Tumor Habitats using Diffusion MRIAcute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort StudyDermal lymphatic invasion and inflammatory breast cancer are independent predictors of outcome after postmastectomy radiation.The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancerHistory of smoking is associated with younger age at diagnosis of breast cancerWeighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate CancerAn Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost VolumesTowards a universal MRI atlas of the prostate and prostate zones : Comparison of MRI vendor and image acquisition parameters
P50
Q36104725-BB3B3022-5D7F-44AA-B7C9-55ADDA36CAC1Q37033096-84D46805-D148-45E2-96E6-F0B7672B56D4Q38408922-3BB83E5E-6A46-4603-8162-7E24D9F00EF6Q39268756-F4DA201D-BA99-471B-9604-6A8CF6110955Q39286582-73B42413-9580-4DA2-8201-5967B3B2C075Q41021469-5F14956B-ABC1-4C52-8882-7A0B65D1B63FQ41743538-66AE65E5-37BF-4ECB-9718-2CD90927665FQ42378371-9A4DAAA6-0020-429E-B970-C4A3D736AC7EQ42602506-CBF031B7-D1C6-45FD-8988-3529EEA81DB0Q45072696-DB8D0B3F-F3DD-4CA3-A73F-0A0703C5B161Q45412370-B7AFC2F5-E662-4F7A-B21D-B8B304697E07Q46212404-D0E06513-6E37-4613-95EB-A84D4C9102C8Q47645461-154C8AB3-7103-403D-AA9A-3008590300B4Q49617541-51DCD970-DA52-4C35-A28E-130A9B8F1B39Q53103459-1CCEF793-5ECD-4E62-B458-6A785F678FE2Q54640902-2A0E843E-6902-424E-95A4-95D98FFFDF21Q57112368-D0205FC4-07E4-4401-821E-ACC40931323EQ57112410-C7E8928C-A72D-43CC-93C8-6A0F45618D6EQ58588190-5CD6FD41-5A41-499C-9411-A8155115F05CQ59136073-901B1F78-FBF4-4147-8DBA-B181C0E0E022Q59138792-369419DD-BC41-42B1-91F3-5D71C772F6C4Q64910547-D855796D-C47A-4056-891E-7B134E1F686BQ81517505-60A54E98-2E80-48CB-BBFC-3FCE6D90EA61Q84159175-7E3A01CC-37BC-44DF-AED7-56A80DD60549Q87457121-15E998FD-7C45-409E-A80F-987D3488A288Q89122960-452F8518-9B4B-48CD-9E04-92BB1E566BE3Q91119683-09CD27BF-FDF6-46EA-9417-782442B558F0
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2632-579X
@en
name
Matthew C Abramowitz
@ast
Matthew C Abramowitz
@en
Matthew C Abramowitz
@es
Matthew C Abramowitz
@nl
type
label
Matthew C Abramowitz
@ast
Matthew C Abramowitz
@en
Matthew C Abramowitz
@es
Matthew C Abramowitz
@nl
prefLabel
Matthew C Abramowitz
@ast
Matthew C Abramowitz
@en
Matthew C Abramowitz
@es
Matthew C Abramowitz
@nl
P106
P1153
36963972300
P31
P496
0000-0002-2632-579X